EICHORCondition: Rheumatoid Arthritis · Sponsor: Diakonhjemmet Hospital
The goal of this clinical trial is to compare therapeutic drug monitoring (TDM) versus Standard of care in patients with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor (adalimumab). The main question it aims to answer is: Is TDM superior to standard of care in order to maintain sustained disease control without flares? Participants will be followed with blood sampling every second month, measuring serum drug levels and anti-drug antibodies of the TNFi. In the TDM-group, the researchers will adjust the dosage of the TNFi based on knowledge on optimal therapeutic ranges. In the Standard of care group, the TNFi will be administered according to standard of care without knowledge of serum drug levels or anti-drug antibodies.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Medical University Vienna | Vienna, Austria | — |
| Humanitas Research Hospital | Milan, Italy | — |
| Diakonhjemmet sykehus | Oslo, N-0319, Norway | — |
| Ålesund Hospital | Ålesund, Norway | — |
| Haukeland University Hospital | Bergen, Norway | — |
| Nordland Hospital Trust | Bodø, Norway | — |
| Drammen Hospital | Drammen, Norway | — |
| Førde Hospital Trust | Førde, Norway | — |
| Haugesund Rheumatism Hospital | Haugesund, Norway | — |
| Hospital of Southern Norway Trust | Kristiansand, Norway | — |
| Lillehammer Hospital for Rheumatic Diseases | Lillehammer, Norway | — |
| Helgeland Hospital Trust | Mo i Rana, Norway | — |
+ 10 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06440629